Chinese eye hospital chain operator Chaoju Ophthalmology has raised RMB400 million ($59 million) in a Series B round of funding backed by Orchid Asia Group and River Head Capital.
Ping An Insurance and CITIC Group have made a Series B investment of undisclosed size in Airdoc, a Chinese medical services company that uses artificial intelligence (AI).
Mercury Capital secured a 15.7x return by helping Australian clinical trials specialist Novotech upgrade its marketing and personnel as well as pursue Asian expansion
CMB International Capital, a private equity unit of China Merchants Bank, has led a $100 million Series B round for US and China-based biopharmaceutical developer Apollomics.
Beijing and Shanghai-based Medbanks, an information service provider specializing in cancer care, has raised RMB400 million ($59 million) in Series C funding led by CLP Fund.
Sequoia Capital China and HighLight Capital have led a RMB550 million ($80 million) pre-IPO funding round for BrightGene Bio-Medical Technology, a Chinese developer of innovative and generic drugs. An investment unit of GF Securities also participated.
Chinese drug developer Antengene wins backing from the likes of Boyu Capital and FountainVest Partners for a pipeline of treatments that address the country's growing cancer problem
Chinese online healthcare services provider Zhiyun Health has raised $100 million in a Series C round of funding across two tranches.
Sanjiv Kaul, who left a career with pharma giant Ranbaxy to become an investor at ChrysCapital Partners, discusses the evolution of operational capabilities in Indian private equity
China-based healthcare care services provider Miaoshou Doctor has raised RMB500 million ($72.8 million) in an extended Series C round of funding led by Starquest Capital, with participation from Sequoia Capital China.
China’s Loyal Valley Capital has led a $160 million funding round for Beijing Innocare, a biotechnology developer focused on immuno-oncology and autoimmune diseases.
New Alliance Capital has led a $45 million Series A round for China-based contract research and manufacturing services provider Thousand Oaks Biopharmaceuticals, with participation by Addor Capital and several other healthcare-focused investors.
Indian venture capital firm Iron Pillar Capital Management has led a $22 million Series D round for Vyome Therapeutics, a domestic pharmaceuticals developer focused on skin diseases.
Advantech Capital has led a $55 million Series B funding round for China’s Connect Biopharmaceuticals with support from Qiming Venture Partners.
Antengene Corporation, a Chinese biopharmaceutical company focused on oncology drugs and therapies, has raised $120 million in a Series B round led by Boyu Capital and FountainVest Partners.
KKR-backed Radiant Life Care is taking majority control of Indian hospital operator Max Healthcare, three months after agreeing to buy a 49.7% stake held by South Africa’s Life Healthcare Group.
Brookfield Asset Management expects to proceed with a A$4.49 billion ($3.16 billion) take-private offer for Australia-listed hospital operator Healthscope, although BGH Capital – which began its pursuit of the company eight months ago – has indicated...
Motilal Oswal Private Equity (MOPE) and healthcare-focused GP Invascent Capital have invested in Indian pharmaceutical developer Symbiotec Pharmalab, providing an exit for Actis Capital.
Shanghai Henlius Biotech, a Chinese drug developer controlled by Fosun Group, has filed for a Hong Kong IPO. Third-party investors include Loyal Valley Capital and China International Capital Corporation (CICC).
Chinese B2B pharmaceutical trading and education platform Yaoshibang has raised $133 million in a Series D round of funding led by Tiger Global Management, H Capital, and DCM.
Shanghai Junshi Biosciences, a Chinese drug developer backed by Hillhouse Capital, is seeking to raise up to HK$3.2 billion ($414 million) through a Hong Kong IPO.
PE-backed WuXi AppTec, a contract pharmaceutical R&D services provider, traded flat on its Hong Kong debut, following an IPO of HK$9.1 billion ($1.1) billion.
CX Partners has led a consortium of private equity investors to commit an undisclosed sum to Indian contract research organization Veeda Clinical Research.
True North has invested INR10 billion ($140 million) in Indian health products manufacturer Zydus Wellness to support its acquisition of Heinz India.